Quality of Life (Qol) Results from the Phase 3 Revel Study of Ramucirumab + Docetaxel (Ram + Dtx) Versus Placebo + Docetaxel (Pl + Dtx) in Advanced/Metastatic Nsclc Patients (Pts) with Progression After Platinum Based Chemotherapy
Makaleler > Tam Makale · 2014
Yazarlar: E.B. Garon, T. Ciuleanu, O. Arrieta, K. Prabhash, K.N. Syrigos, Tuncay GÖKSEL, K. Park, R. Kowalyszyn, J. Pikiel, C. Lewanski, M. Thomas, S. Dakhil, J. Kim, N. Karaseva, S. Yurasov, A. Zimmermann, G. Cuyun Carter, M. Reck, F. Cappuzzo, M. Perol
Annals of Oncology, Uluslararası, Wos, 2014, cilt 25, ss iv445-iv445